Metabolic profiling to evaluate the impact of amantadine and rimantadine on the secondary metabolism of a model organism.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 10 2023
05 10 2023
Historique:
received:
20
06
2023
accepted:
25
09
2023
medline:
2
11
2023
pubmed:
6
10
2023
entrez:
5
10
2023
Statut:
epublish
Résumé
Metabolic profiling offers huge potential to highlight markers and mechanisms in support of toxicology and pathology investigations during drug development. The main objective was to modify therapy with adamantane derivatives: amantadine and rimantadine, to increase their bioavailability and evaluate the influence of such therapy on drug metabolism using Saccharomyces cerevisiae as the model organism. In this study, the profile of endogenous metabolites of a model organism was measured and interpreted to provide an opportunity to investigate changes induced by treatment with amantadine and rimantadine. It was found that resveratrol supplementation synergistically enhanced the effects of amantadine treatment and increased rimantadine metabolism, potentially reducing side effects. The fingerprinting strategy was used as an efficient technique for qualitatively evaluating and monitoring changes in the profiles of endogenous components and their contents in a model organism. Chemometric tools were employed to find marker compounds that can be defined as characteristic indicators of a pharmacological response to a therapeutic intervention. An improved understanding of the mechanisms involved in drug effect and an increased ability to predict individual variations in the drug response of organisms will improve the treatment process and the development of new therapies.
Identifiants
pubmed: 37798340
doi: 10.1038/s41598-023-43540-w
pii: 10.1038/s41598-023-43540-w
pmc: PMC10555991
doi:
Substances chimiques
Rimantadine
0T2EF4JQTU
Adamantane
PJY633525U
Amantadine
BF4C9Z1J53
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16822Informations de copyright
© 2023. Springer Nature Limited.
Références
Curr Opin Genet Dev. 2017 Jun;44:74-83
pubmed: 28232272
Biochim Biophys Acta. 2006 Dec;1763(12):1364-73
pubmed: 17050005
Int J Infect Dis. 2022 Nov;124:143-151
pubmed: 36152957
Sci Rep. 2022 Jun 29;12(1):10978
pubmed: 35768453
Brain Res Bull. 1981 Feb;6(2):141-3
pubmed: 7470959
Eur J Med Chem. 2023 Jan 15;246:114962
pubmed: 36463729
Eur J Med Chem. 2021 Nov 5;223:113655
pubmed: 34175536
Lancet Neurol. 2021 Jan;20(1):38-48
pubmed: 33242419
Eur J Pharmacol. 1974 Feb;25(2):185-90
pubmed: 4435022
Biochem Biophys Res Commun. 2023 Feb 12;644:130-139
pubmed: 36641965
Pharmacol Biochem Behav. 2022 Jun;217:173393
pubmed: 35513119
Mol Cell Neurosci. 2022 Sep;122:103757
pubmed: 35843531
Life Sci. 2023 Apr 15;319:121410
pubmed: 36681185
Metab Eng. 2015 Nov;32:1-11
pubmed: 26344106
Braz J Psychiatry. 2018 Oct-Dec;40(4):449-458
pubmed: 29898194
Biochem Pharmacol. 1972 Jan;21(1):77-87
pubmed: 5058704
J Biol Chem. 2022 Oct;298(10):102410
pubmed: 36007612
Curr Opin Biotechnol. 2020 Jun;63:63-69
pubmed: 31901548
Nature. 2006 Apr 20;440(7087):1073-7
pubmed: 16625200
Psychiatry Res. 1989 Jul;29(1):11-6
pubmed: 2672061
Ageing Res Rev. 2023 Mar;85:101863
pubmed: 36707034
Biotechnol J. 2008 Mar;3(3):325-38
pubmed: 18228539
Drug Resist Updat. 2021 Dec;59:100794
pubmed: 34991982
Am J Ophthalmol Case Rep. 2020 Aug 05;19:100852
pubmed: 32875144
Brain Res Bull. 1989 Oct-Nov;23(4-5):267-71
pubmed: 2590838
Biochim Biophys Acta. 2013 Nov-Dec;1827(11-12):1346-61
pubmed: 23220121
Eur J Med Chem. 2018 Feb 25;146:123-138
pubmed: 29407944
Behav Brain Res. 2015 Feb 15;279:274-82
pubmed: 25447294
Behav Brain Res. 2023 Mar 28;442:114309
pubmed: 36706808
J Nutr Biochem. 2022 Oct;108:109083
pubmed: 35691595
Sci Rep. 2023 Jan 26;13(1):1473
pubmed: 36702867